Olutasidenib Combined With Co-targeted Therapy in Relapsed or Refractory IDH1-mutated Myeloid Malignancies Harboring Activated Signaling Pathway Mutations
NCT07032727
IDH1-Mutated Malignancies, Mutations
Houston, Texas, United States
View Trial Details